Can Psoriasis Therapy Lower CV Event Risk in Psoriasis Patients?
Patients with psoriasis treated with tumor necrosis factor-alpha inhibitors (TNFis) had a significantly lower risk for cardiovascular events compared with patients treated with phototherapy, according to the findings of a recent study.
In their observational study, the researchers identified patients with psoriasis using a large US administrative claims database. Patients were separated into 2 cohorts based on whether they were treated with TNFis (n=11,410) or phototherapy (n=12,433). The researchers used multivariate Cox proportional hazards models to compare the cardiovascular event risk between the 2 cohorts.
Psoriasis Patients Underdiagnosed For CV Risk Factors
Psoriasis Therapy Significantly Reduces Aortic Inflammation
Compared with patients treated with phototherapy, those treated with TNFis had a lower risk for cardiovascular events (adjusted hazard ratio: 0.77). The risk reduction associated with 6 months of cumulative exposure was 11.2% larger for patients treated with TNFis compared to phototherapy (p<0.05).
“Psoriasis patients treated with TNFis exhibited a lower cardiovascular event risk than patients treated with phototherapy,” the researchers concluded. “Cumulative exposure to TNFis was associated with an incremental cardiovascular risk reduction compared to phototherapy.”
Wu JJ, Sundaram M, Cloutier M, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort study [published online February 27, 2018]. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.02.050.